PRESSEPORTAL Presseportal Logo

mehr Themen

Storys zum Thema Enterprises

Folgen
Keine Story zum Thema Enterprises mehr verpassen.
Warum muss ich meine Email-Adresse eingeben?
Filtern
  • 25.01.2010 – 09:02

    Agence de Medecine Preventive (AMP)

    AMP Supports the Creation of a National Immunization Technical Advisory Group in Côte d'Ivoire

    Paris (ots/PRNewswire) - On January 15, the Minister of Health and Hygiene of Côte d'Ivoire, Dr. Rémi Allah Kouadio, presided over a ceremony to mark the launch of a National Immunization Technical Advisory Group (NITAG) named "Côte d'Ivoire National Committee of Independent Experts for Vaccination and Vaccines" (Comité National d'Experts Indépendants pour la ...

    mehr
  • 21.01.2010 – 21:55

    Abbott Laboratories

    Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries

    Abbott Park, Illinois (ots/PRNewswire) - Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines containing sibutramine. Abbott will comply with the CHMP recommendation and suspend the marketing of Abbott medicines containing ...

    mehr
  • 21.01.2010 – 11:01

    AVEVA

    WorleyParsons Significantly Increases Usage of AVEVA Plant Solutions

    Kuala Lumpur, Malaysia (ots/PRNewswire) - AVEVA Group plc , one of the world's leading providers of engineering data and design IT systems, announced that WorleyParsons, a global provider of technical, project and operational support services, recently signed a contract to significantly increase the company's usage of AVEVA Plant solutions. This new contract ...

    mehr
  • 20.01.2010 – 13:02

    Bank of America Corporation

    Bank of America Announces 2009 Net Income of US$6.3 Billion

    Charlotte, North Carolina (ots/PRNewswire) - Bank of America Corporation today reported full-year 2009 net income of US$6.3 billion, compared with net income of US$4.0 billion in 2008. Including preferred stock dividends and the negative impact from the repayment of the U.S. government's US$45 billion preferred stock investment in the company under the Troubled Asset Relief Program (TARP), income applicable to common ...

    mehr
  • 18.01.2010 – 11:03

    AVEVA

    AVEVA Announces Stronger Partnership With Z+F

    Cambridge, England (ots/PRNewswire) - AVEVA and Z+F are pleased to announce a stronger technical and commercial partnership, focused on delivering new levels of integration and productivity between laser scanning, detailed design and asset management. Z+F specializes in 3D laser scanning and was one of the first companies to release a phase based laser scanner and subsequently invented the world's 1st stand alone ...

    mehr
  • 15.01.2010 – 22:39

    Canada Lands Company

    CN Tower Supports Haiti Disaster Relief Efforts

    Toronto (ots/PRNewswire) - To raise awareness of the need to support Haiti's earthquake survivors, Canada's National Tower will be lit in red and blue, the colours of the flag of Haiti, beginning at sunset each night from January 15-22, 2010. The CN Tower will also raise awareness of relief efforts on site by providing visitors with opportunities to donate to the Canadian Red Cross. Visitors can add a donation at ...

    mehr
  • 15.01.2010 – 21:56

    DEW Engineering and Development ULC

    GDLS-C Provides $39.5M Order to DEW for Stryker Armour

    Ottawa (ots/PRNewswire) - DEW Engineering and Development ULC, with headquarters in Ottawa and additional manufacturing facilities in Miramichi, New Brunswick, recently received a $39.5M purchase order from General Dynamics Land Systems Canada (GDLS-C) to provide ceramic composite hull armour kits for 352 Stryker armoured vehicles. Since 2003, DEW has been the exclusive supplier of the ceramic composite armour ...

    mehr
  • 14.01.2010 – 14:02

    ICS Copper Systems Ltd

    ICS Issues Stock Options to New Director

    Abbotsford, Canada (ots/PRNewswire) - At the Directors' meeting on January 6, 2010, the Company issued 375,000 options to Markus Janser at an exercise price of CDN$0.10 per share. These options will expire on January 6th, 2015. The Company has 501,387 options remaining for issuance under their existing Incentive Stock Option Plan. Mr. Markus Janser was appointed as a Director at the Company's AGM on December 22, ...

    mehr
  • 14.01.2010 – 11:02

    AVEVA

    AVEVA Releases Finite Element Analysis Interface for Shipbuilders

    Cambridge, England (ots/PRNewswire) - AVEVA announces the release of AVEVA Hull Finite Element Modeller, a powerful new addition to the AVEVA Marine portfolio which accelerates and simplifies the stress analysis of ship structures. Ship designers rely on the use of Finite Element Analysis (FEA) to ensure that hull structures comply with rigorous strength ...

    mehr
  • 13.01.2010 – 11:02

    AVEVA

    AVEVA Releases Powerful New 3D Design Transfer Solution

    Cambridge, England (ots/PRNewswire) - AVEVA announces the release of AVEVA Mechanical Equipment Interface, a powerful solution to the problem of transferring 3D models between incompatible design systems. Until now, solutions for transferring design between different 3D CAD systems have proved to be inadequate in various ways and have not achieved the necessary high levels of usability or industry ...

    mehr
  • 11.01.2010 – 14:31

    Advanced Cardiac Therapeutics

    Advanced Cardiac Therapeutics Completes $5 Million Financing

    Laguna Beach, California (ots/PRNewswire) - Advanced Cardiac Therapeutics, Inc. ("ACT"), a developer of advanced irrigated cardiac ablation systems, announced today that it has completed a $5 million 'Series B' equity financing. The financing was led by NBGI Ventures, a venture capital firm specialized in medical technology investments, and is expected to fund commercialisation in Europe. ACT was founded in 2007 to ...

    mehr
  • 11.01.2010 – 12:00

    Helsinn Healthcare SA

    The Helsinn Group Implements New Organizational Structure

    Lugano (ots) - Giorgio Calderari promoted to Group General Manager, responsible for Corporate, Business Development, R&D, Technical Affairs, Commercial, and Manufacturing functions Riccardo Braglia has been confirmed as CEO of the Helsinn Group. His role will focus on the Group's fundamental strategic tasks, including internal and external growth, and new market opening. Riccardo Braglia will also directly ...

    mehr
  • 06.01.2010 – 20:27

    Abbott Laboratories

    New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark

    Des Plaines, Illinois (ots/PRNewswire) - Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that detects the methylated form of Septin 9, a gene linked to colorectal cancer, in blood specimens. The product is not available for sale in the United States. The RealTime mS9 ...

    mehr
  • 29.12.2009 – 06:50

    BNK Petroleum Inc.

    BNK Petroleum Inc. Adds a Sixth European Shale Gas Concession

    Calgary, Canada (ots/PRNewswire) - BNK Petroleum Inc. ("BNK" or the "Company") is pleased to announce that it has been awarded an additional 300,000 acre oil and gas concession in a European Union country. The granting of this concession brings BNK's 2009 total land acquisitions in Europe to 1.4 million acres, and provides further diversification by now having projects in 3 distinct basins. In accordance with ...

    mehr
  • 22.12.2009 – 20:34

    Resverlogix Corp.

    Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial

    Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD). This study is chaired by Dr. Steven Nissen, MD, Chairman ...

    mehr
  • 22.12.2009 – 10:01

    ConvaTec, international

    ConvaTec Appoints Erik Zimmer Vice President and General Manager

    Paris (ots/PRNewswire) - ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced that Erik Zimmer has joined the company as Vice President and General Manager within its European, Middle East and Africa (EMEA) region. Based in Paris, Zimmer will have responsibility for a newly designated region within EMEA, consisting of France, Benelux, ...

    mehr
  • 21.12.2009 – 13:01

    Medicago

    Medicago Reports Positive Phase I Results for its Avian Flu Pandemic Vaccine

    Quebec City (ots/PRNewswire) - Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The ...

    mehr
  • 21.12.2009 – 08:05

    TAG Heuer SA

    Tag Heuer Stands by Brand Ambassador Tiger Woods

    LE CHAUX- DE-FONDS, Switzerland, December 21 (ots/PRNewswire) - Unlike the misleading information issued on December 18th by Associated Press, TAG Heuer confirms it will continue its partnership with Tiger Woods, as per the following press release. (Photo: http://www.newscom.com/cgi-bin/prnh/20091221/371511 ) TAG Heuer confirms that it will continue its relationship with Golf no.1 Tiger Woods but will respect ...

    mehr
  • 17.12.2009 – 14:19

    Agendia B.V.

    FDA Broadens Clearance for Agendia's MammaPrint(R)

    Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past three years, the FDA has issued four clearances for ...

    mehr